Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Jan 12, 2015 at 11:35 AM EST

Is the Merger a Great Deal for Tekmira Shareholders?

Tekmira Pharmaceuticals and OnCore Biopharma have announced that they will merge to form a new company to develop a curative…

Chris Lange | Jan 9, 2015 at 1:55 PM EST

Has Agenus Run Too Much?

Agenus, in conjunction with Incyte, announced a global license for the development and commercialization of Agenus's proprietary Retrocyte Display antibody…

Jon C. Ogg | Jan 9, 2015 at 11:50 AM EST

The Bullish and Bearish Case for UnitedHealth in 2015

As the nation's largest health insurance provider, UnitedHealth is often front and center in the fight or review of the…

Jon C. Ogg | Jan 9, 2015 at 11:25 AM EST

The Bullish and Bearish Case for Pfizer in 2015

One key consideration for the year ahead is that the Pfizer of 2016 or 2017 is likely to be night…

Chris Lange | Jan 9, 2015 at 11:00 AM EST

Gilead Continues to Recover from Express Scripts Loss

Gilead Sciences was picked up by Anthem to provide its hepatitis C drug as the primary option for patients.

Lee Jackson | Jan 9, 2015 at 10:30 AM EST

Analyst’s Top 3 Biotech Picks for 2015 With Upside and Takeover Potential

A recent research piece from the biotech analysts at Stifel focused on three top stocks to buy with outstanding potential.

Paul Ausick | Jan 8, 2015 at 11:35 AM EST

The Bullish and Bearish Case for Merck in 2015

One key consideration for the year ahead is Merck's acquisitions of Idenix and Cubist Pharmaceuticals to expand its product offerings

Chris Lange | Jan 8, 2015 at 10:25 AM EST

6 Serious Biotech and Health Care Movers

In Thursday morning’s trading session, it seemed almost across the board that biotech stocks were the largest gainers.

Chris Lange | Jan 8, 2015 at 8:50 AM EST

GW Cannabinoid Drug Fails Cancer Pain Trial

GW Pharmaceuticals reported top-line results from the first of three Phase 3 trials for Sativex.

Chris Lange | Jan 7, 2015 at 2:51 PM EST

Wells Fargo’s Top Biotech Stocks for 2015

ThinkstockLooking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech…

Chris Lange | Jan 7, 2015 at 1:35 PM EST

Is Immunomedics Worth 50% More?

After Immunomedics announced that it had appointed a new chief medical officer, Wells Fargo issued an analyst call implying upside…

Lee Jackson | Jan 7, 2015 at 10:35 AM EST

Analyst’s 8 Top Health Care Stocks for 2015

A new research report from the analysts at Cowen highlights the firm's top health care picks, many of which have…

Chris Lange | Jan 5, 2015 at 4:25 PM EST

Is a Generic Diovan for You?

What are investors, and patients, supposed to think when is launching a generic version of Diovan?

Chris Lange | Jan 5, 2015 at 4:19 PM EST

Rite Aid Scores New Street-High Analyst Price Target

Pharmacy and drug store player Rite Aid now has a new street-high analyst target price from Credit Suisse.

Chris Lange | Dec 31, 2014 at 8:40 AM EST

New Biotech ETF Hits the Market

The ALPS Medical Breakthroughs ETF debuted on the market Wednesday and is focused on research and development opportunities in biotechnology…

1 … 272 273 274 275 276 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Is the Merger a Great Deal for Tekmira Shareholders?

Has Agenus Run Too Much?

The Bullish and Bearish Case for UnitedHealth in 2015

The Bullish and Bearish Case for Pfizer in 2015

Gilead Continues to Recover from Express Scripts Loss

Analyst’s Top 3 Biotech Picks for 2015 With Upside and Takeover Potential

The Bullish and Bearish Case for Merck in 2015

6 Serious Biotech and Health Care Movers

GW Cannabinoid Drug Fails Cancer Pain Trial

Wells Fargo’s Top Biotech Stocks for 2015

Is Immunomedics Worth 50% More?

Analyst’s 8 Top Health Care Stocks for 2015

Is a Generic Diovan for You?

Rite Aid Scores New Street-High Analyst Price Target

New Biotech ETF Hits the Market

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

FedEx Slides 9%, UPS Sinks 10% as Amazon Supply Chain Services Goes Live: How Real Is the Threat?

GameStop ($11B Market Cap) Makes $56B Offer for eBay

Qualcomm’s Path to $208 Runs Through Record Automotive Growth

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Ben Carlson Calls Out the Goldman Survey That Says 40% of $500K Earners Live Paycheck-to-Paycheck. The Definition Is the Problem.

FedEx Slides 9%, UPS Sinks 10% as Amazon Supply Chain Services Goes Live: How Real Is the Threat?

GameStop ($11B Market Cap) Makes $56B Offer for eBay

Health and Healthcare Articles

All Health and Healthcare Articles

Is the Merger a Great Deal for Tekmira Shareholders?

Has Agenus Run Too Much?

The Bullish and Bearish Case for UnitedHealth in 2015

The Bullish and Bearish Case for Pfizer in 2015

Gilead Continues to Recover from Express Scripts Loss

Analyst’s Top 3 Biotech Picks for 2015 With Upside and Takeover Potential

The Bullish and Bearish Case for Merck in 2015

6 Serious Biotech and Health Care Movers

GW Cannabinoid Drug Fails Cancer Pain Trial

Wells Fargo’s Top Biotech Stocks for 2015

Is Immunomedics Worth 50% More?

Analyst’s 8 Top Health Care Stocks for 2015

Is a Generic Diovan for You?

Rite Aid Scores New Street-High Analyst Price Target

New Biotech ETF Hits the Market

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

FedEx Slides 9%, UPS Sinks 10% as Amazon Supply Chain Services Goes Live: How Real Is the Threat?

GameStop ($11B Market Cap) Makes $56B Offer for eBay

Qualcomm’s Path to $208 Runs Through Record Automotive Growth

Featured Reads

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Ben Carlson Calls Out the Goldman Survey That Says 40% of $500K Earners Live Paycheck-to-Paycheck. The Definition Is the Problem.